Abstract
Since the emergence of the novel coronavirus, named COVID-19, researchers are looking for a treatment to stop the evastating pandemic. During these efforts, mesenchymal stem cells (MSCs), the potential next generation of therapeutic methods with wide application for diseases, have successfully controlled cytokine storm following the virus infection. However, the use of MSCs has been limited due to the ethical issues, immunogenicity, and genetic modifications. Therefore, exosomes were introduced as a suitable substitute for the MSCs. In the case of COVID-19 treatment, both MSCs and several preclinical and clinical studies of exosomes for COVID-19 treatment.
Author supplied keywords
Cite
CITATION STYLE
Kiaie, N., Ghanavati, S. P. M., Miremadi, S. S., Hadipour, A., & Aghdam, R. M. (2021). Mesenchymal Stem Cell-Derived Exosomes For Covid-19 Therapy, Preclinical And Clinical Evidence. International Journal of Stem Cells, 14(3), 252–261. https://doi.org/10.15283/IJSC20182
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.